Bright Angel Therapeutics is a pre-clinical stage biotechnology company focused on the development of novel therapeutics for the treatment of drug-resistant and life-threatening fungal infections. Fungi infect billions and kill 1.5M people per year, as many as tuberculosis or malaria yet only three classes of antifungal drugs have been approved to date. Resistance against all three classes has been seen in the clinic and is now a major impediment to treatment. They are designing novel drugs that target key regulatory proteins involved in the antifungal stress response as it has been shown that an intact fungal stress response is needed for the emergence and maintenance of antifungal drug resistance.